Exploring Guzelcomab Studies at ACR 2024

This chapter highlights the ACR 2024 meeting with a focus on guzelcomab's impact on Psoriatic Arthritis treatment. Experts present findings on treatment effectiveness, comparisons to IL-17 inhibitors, and patient-reported outcomes, illustrating guzelcomab's clinical benefits.